Recombinant Human soluble Tumor Necrosis Factor-Related Apoptosis-inducing Ligand Receptor-2/TNFRSF10B

Synonyms soluble TRAIL Receptor-2, DR5, TNFRSF10B, KILER, TRICK2A, TRICKB

Accession O14763

GeneID 8795

Source Escherichia coli.

Molecular Weight Approximately 14.8 kDa, a single non-glycosylated polypeptide chain containing 132 amino acids.

Quantity 10µg/50µg/1mg

AA Sequence ESALITQQDL APQQRAAPQQ KRSSPSEGLC PPGHHISEDG RDCISCKYGQ DYSTHWNDLL FCLRCTRCDS GEVELSPCTT TRNTVCQCEE GTFREEDSPE MCRKCRTGCP RGMVKVGDCT PWSDIECVHK ES

Purity > 97 % by SDS-PAGE and HPLC analyses.

Biological Activity Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Endotoxin Less than 1 EU/μg of rHusTRAIL-R2 as determined by LAL method.

Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

SDS-PAGE

Reference 1. Pordzik S, Petrovici K, Schmid C, et al. 2011. Hematology, 16: 341-50.

2. Tseng HY, Chen LH, Ye Y, et al. 2012. Carcinogenesis, 33: 1871-81.

3. Bae SI, Cheriyath V, Jacobs BS, et al. 2008. Oncogene, 27: 490-8.

4. Camidge DR. 2008. Expert Opin Biol Ther, 8: 1167-76.

Background Tumor necrosis factor-related apoptosis-inducing ligand Receptor 2 (TRAIL-R2) is a cell-surface receptor involved in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell-death signaling. The death ligand TRAIL bears high potential as a new anticancer agent, as binding to the death receptors TRAIL-R1 or TRAIL-R2 triggers apoptosis in most cancer cells. TRAIL-R2 has been shown to be associated with a decrease in the survival rates of breast cancer patients.